These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 19296774)

  • 1. Adaptive designs for randomized trials in public health.
    Brown CH; Ten Have TR; Jo B; Dagne G; Wyman PA; Muthén B; Gibbons RD
    Annu Rev Public Health; 2009; 30():1-25. PubMed ID: 19296774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop.
    Coffey CS; Levin B; Clark C; Timmerman C; Wittes J; Gilbert P; Harris S
    Clin Trials; 2012 Dec; 9(6):671-80. PubMed ID: 23250942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Essential Ingredients and Innovations in the Design and Analysis of Group-Randomized Trials.
    Murray DM; Taljaard M; Turner EL; George SM
    Annu Rev Public Health; 2020 Apr; 41():1-19. PubMed ID: 31869281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of the epidemiology methods and applications: strengths and limitations of observational study designs.
    Colditz GA
    Crit Rev Food Sci Nutr; 2010; 50 Suppl 1(s1):10-2. PubMed ID: 21132580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Panel discussion 1.
    Dickersin K; Williams G; George S
    Clin Trials; 2012 Dec; 9(6):696-704. PubMed ID: 23250943
    [No Abstract]   [Full Text] [Related]  

  • 8. Large clinical trials in epilepsy: funding by the NIH versus pharmaceutical industry.
    Privitera M
    Epilepsy Res; 2006 Jan; 68(1):52-6. PubMed ID: 16377139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accrual to cancer clinical trials: directions from the research literature.
    Gotay CC
    Soc Sci Med; 1991; 33(5):569-77. PubMed ID: 1962228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adaptive Bayesian randomized trials: realizing their potential.
    Pullenayegum EM
    J Bone Joint Surg Am; 2012 Jul; 94 Suppl 1():29-33. PubMed ID: 22810444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statistical lessons learned for designing cluster randomized pragmatic clinical trials from the NIH Health Care Systems Collaboratory Biostatistics and Design Core.
    Cook AJ; Delong E; Murray DM; Vollmer WM; Heagerty PJ
    Clin Trials; 2016 Oct; 13(5):504-12. PubMed ID: 27179253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ethics and practice of Trials within Cohorts: An emerging pragmatic trial design.
    Kim SY; Flory J; Relton C
    Clin Trials; 2018 Feb; 15(1):9-16. PubMed ID: 29224380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethical issues in the design and conduct of stepped-wedge cluster randomized trials in low-resource settings.
    Joag K; Ambrosio G; Kestler E; Weijer C; Hemming K; Van der Graaf R
    Trials; 2019 Dec; 20(Suppl 2):703. PubMed ID: 31852547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stakeholder views regarding ethical issues in the design and conduct of pragmatic trials: study protocol.
    Nicholls SG; Carroll K; Brehaut J; Weijer C; Hey SP; Goldstein CE; Zwarenstein M; Graham ID; McKenzie JE; McIntyre L; Jairath V; Campbell MK; Grimshaw JM; Fergusson DA; Taljaard M
    BMC Med Ethics; 2018 Nov; 19(1):90. PubMed ID: 30458809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs of clinical trials and the need for efficiency: a brief overview.
    Friedewald WT
    Stat Med; 1990; 9(1-2):9-12. PubMed ID: 2345842
    [No Abstract]   [Full Text] [Related]  

  • 16. Response-adaptive decision-theoretic trial design: operating characteristics and ethics.
    Lipsky AM; Lewis RJ
    Stat Med; 2013 Sep; 32(21):3752-65. PubMed ID: 23558674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design issues in randomized phase II/III trials.
    Korn EL; Freidlin B; Abrams JS; Halabi S
    J Clin Oncol; 2012 Feb; 30(6):667-71. PubMed ID: 22271475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New opportunities and proven approaches in complementary and alternative medicine research at the National Institutes of Health.
    Harlan WR
    J Altern Complement Med; 2001; 7 Suppl 1():S53-9. PubMed ID: 11822636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conducting Value for Money Analyses for Non-randomised Interventional Studies Including Service Evaluations: An Educational Review with Recommendations.
    Franklin M; Lomas J; Richardson G
    Pharmacoeconomics; 2020 Jul; 38(7):665-681. PubMed ID: 32291596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ethical and regulatory issues of pragmatic cluster randomized trials in contemporary health systems.
    Anderson ML; Califf RM; Sugarman J;
    Clin Trials; 2015 Jun; 12(3):276-86. PubMed ID: 25733677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.